November 12, 2013
Launched in November last year, Eylea (aflibercept) has overtaken its archrival Lucentis (ranibizumab) to snatch the top spot in the Japanese market for ophthalmic vascular endothelial growth factor (VEGF) inhibitors, Santen Pharmaceutical revealed. At an earnings briefing on November 8,...read more